Besides autoantibodies, an increase in serum or BALF of a biomarker of pulmonary origin may be able to predict or reflect the development of fibrosis, the impairment of lung function, and ideally also the prognosis. PubMed, Semin Respir Crit Care Med, 2014 Apr;35(2):181-200. (Also see: Pulmonary Fibrosis Research and Biomarkers)
This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.